Rotem Elgavish, MD
Neurology · Lone Tree, CONPI 1437366473
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,547 of the $124,817 with a category attached, or 85.4%. 25 manufacturers reported payments, led by Eisai Inc. at 30.1% of the total. Reporting peaked in 2019 at $72,872 and has fallen 99.1% since, to $643 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $394.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$38K
- Neurelis, Inc.$36K
- Aquestive Therapeutics, Inc.$27K
- Sunovion Pharmaceuticals Inc.$22K
- ZOLL Medical Corporation$440
- SK Life Science, Inc.$408
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,0472%
- Speaking & faculty fees$106,54785%
- Travel & lodging$10,8489%
- Food & beverage$5,3754%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 72 | $37,585 |
| Neurelis, Inc. | 53 | $35,550 |
| Aquestive Therapeutics, Inc. | 87 | $27,138 |
| Sunovion Pharmaceuticals Inc. | 42 | $21,710 |
| ZOLL Medical Corporation | 1 | $440 |
| SK Life Science, Inc. | 11 | $408 |
| Vertex | 1 | $407 |
| UCB, Inc. | 13 | $345 |
| Livanova USA, Inc. | 4 | $203 |
| Amneal Pharmaceuticals LLC | 2 | $196 |
| Sanofi | 4 | $182 |
| Neurocrine Biosciences, Inc. | 2 | $138 |
| Jazz Pharmaceuticals Inc. | 5 | $111 |
| Neuropace, Inc. | 1 | $92 |
| Amgen | 3 | $54 |
| Lundbeck LLC | 2 | $49 |
| AbbVie(2 entities) | 2 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Lilly USA, LLC | 2 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 2 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| AstraZeneca | 1 | $16 |
| Abbott | 1 | $13 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,817 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 40 | $1,321 |
| Lacosamide | 12 | $763 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lone Tree
- Beverly GilderLone Tree$558K
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Jeffrey BennettAurora$605K
- Michael AmentDenver$457K
- Enrique AlvarezAurora$407K
- Adam WolffDenver$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.